OBINUTUZUMAB (GA101) OR RITUXIMAB (R) plus CHLORAMBUCIL (CLB) VERSUS CLB ALONE IN PATIENTS WITH CLL AND PRE-EXISTING MEDICAL CONDITIONS (COMORBIDITIES): FINAL STAGE 1 RESULTS OF THE CLL11 PHASE 3 TRIAL

被引：0
|
作者：
Goede, V. [1 ]
Fischer, K. [1 ]
Humphrey, K. [2 ]
Asikanius, E. [3 ]
Busch, R. [4 ]
Engelke, A. [1 ]
Wendtner, C. [5 ]
Samoylova, O. [6 ]
Chagorova, T. [7 ]
Dilhuydy, M. [8 ]
De La Serna, J. [9 ]
Illmer, T.
Opat, S. [10 ]
Owen, C. [11 ]
Kreuzer, K. [12 ]
Langerak, A. [13 ]
Ritgen, M. [14 ]
Stilgenbauer, S. [15 ]
Wenger, M. [3 ]
Hallek, M. [1 ]
机构：
[1] Univ Hosp Cologne, Dept Internal Med 1, German CLL Study Grp, Cologne, Germany
[2] F Hoffmann La Roche Ltd, Med Affairs, Welwyn Garden City, England
[3] F Hoffmann La Roche Ltd, Med Affairs, Basel, Switzerland
[4] Tech Univ Munich, Inst Med Stat & Epidemiol, Munich, Germany
[5] Schwabing Hosp Munich, Dept Hematol & Oncol, Munich, Germany
[6] Reg Clin Hosp, Hematol, Nizhnii Novgorod, Russia
[7] Penza Reg Oncol Dispensary, Dept Med, Penza, Russia
[8] Hop Haut Leveque, Hematol Clin, Pessac, France
[9] Hosp Univ 12 Octubre, Serv Hematol, Madrid, Spain
[10] Monash Med Ctr, Haematol, Clayton, Vic, Australia
[11] Tom Baker Canc Clin, Calgary, AB, Canada
[12] Univ Hosp Cologne, Ctr Integrated Oncol Cologne Bonn, Dept Internal Med 1, Cologne, Germany
[13] Erasmus MC, Dept Immunol, Rotterdam, Netherlands
[14] Univ Schleswig Holstein, City Hosp Kiel, Med Dept 2, Kiel, Germany
[15] Univ Ulm, Dept Internal Med 3, Ulm, Germany
来源：
HAEMATOLOGICA | 2013年 / 98卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
S567
引用
收藏
页码：237 / 237
页数：1
相关论文
共 10 条
  • [1] Obinutuzumab (GA101) plus chlorambucil (Clb) versus rituximab plus Clb in patients with chronic lymphocytic leukaemia (CLL) and comorbidities: recently published results of the CLL11 trial
    Goede, V.
    Fischer, K.
    Busch, R.
    Engelke, A.
    Eichhorst, B.
    Wendtner, C. M.
    Chagorova, T.
    Dela Serna, J.
    Dilhuydy, M. S.
    Opat, S.
    Owen, C. J.
    Samoylova, O.
    Kreuzer, K. A.
    Langerak, A. W.
    Ritgen, M.
    Stilgenbauer, S.
    Doehner, H.
    Asikanius, E.
    Humphrey, K.
    Wenger, M. K.
    Hallek, M.
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 165 : 19 - 19
  • [2] Obinutuzumab (GA101) plus chlorambucil (Clb) or rituximab (R) plus Clb versus Clb alone in patients with chronic lymphocytic leukemia (CLL) and preexisting medical conditions (comorbidities): Final stage 1 results of the CLL11 (BO21004) phase III trial.
    Goede, Valentin
    Fischer, Kirsten
    Humphrey, Kathryn
    Asikanius, Elina
    Busch, Raymonde
    Engelke, Anja
    Wendtner, Clemens M.
    Samoylova, Olga
    Chagorova, Tatiana
    Dilhuydy, Marie-Sarah
    Torroba, Javier De La Serna
    Illmer, Thomas
    Opat, Stephen
    Owen, Carolyn
    Kreuzer, Karl A.
    Langerak, Anton W.
    Ritgen, Matthias
    Stilgenbauer, Stephan
    Wenger, Michael
    Hallek, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [3] Head-To-Head Comparison Of Obinutuzumab (GA101) Plus Chlorambucil (Clb) Versus Rituximab Plus Clb In Patients With Chronic Lymphocytic Leukemia (CLL) and Co-Existing Medical Conditions (Comorbidities): Final Stage 2 Results Of The CLL11 Trial
    Goede, Valentin
    Fischer, Kirsten
    Busch, Raymonde
    Engelke, Anja
    Eichhorst, Barbara
    Wendtner, Clemens M.
    Chagorova, Tatiana
    De la Serna, Javier
    Dilhuydy, Marie-Sarah
    Opat, Stephen
    Owen, Carolyn J.
    Samoylova, Olga
    Kreuzer, Karl-Anton
    Langerak, Anton W.
    Ritgen, Matthias
    Stilgenbauer, Stephan
    Doehner, Hartmut
    Asikanius, Elina
    Humphrey, Kathryn
    Wenger, Michael K.
    Hallek, Michael
    BLOOD, 2013, 122 (21)
  • [4] Salvage Therapy with Obinutuzumab (GA101) Plus Chlorambucil (Clb) after Treatment Failure of Clb Alone in Patients with Chronic Lymphocytic Leukemia (CLL) and Comorbidities: Results of the CLL11 Study
    Goede, Valentin
    Engelke, Anja
    Fischer, Kirsten
    Lopez Jimenez, Javier
    Kuzmin, Alexej
    Dyer, Martin J. S.
    Le Du, Katell
    Liberati, Anna Marina
    Schlag, Rudolf
    Langerak, Anton W.
    Ritgen, Matthias
    Stilgenbauer, Stephan
    Asikanius, Elina
    Humphrey, Kathryn
    Wenger, Michael K.
    Fingerle-Rowson, Guenter
    Hallek, Michael
    BLOOD, 2014, 124 (21)
  • [5] RPS15 mutations and Treatment Outcome in Chronic Lymphocytic Leukemia - Results from the CLL11 Phase III Trial (Chlorambucil (Clb) with or without the Addition of Rituximab (R) or Obinutuzumab (GA101, G)) of the German CLL Study Group
    Estenfelder, Sven
    Holland-Letz, Ann-Kathrin
    Tausch, Eugen
    Robrecht, Sandra
    Bahlo, Jasmin
    Goede, Valentin
    Opatrna, Veronika
    Ritgen, Matthias
    van Dongen, Jacques J. M.
    Langerak, Anton W.
    Fingerle-Rowson, Gunter
    Kneba, Michael
    Fischer, Kirsten
    Hallek, Michael
    Dohner, Hartmut
    Stilgenbauer, Stephan
    BLOOD, 2017, 130
  • [6] Gene Mutations and Treatment Outcome in the Context of Chlorambucil (Clb) without or with the Addition of Rituximab (R) or Obinutuzumab (GA-101, G) - Results of an Extensive Analysis of the Phase III Study CLL11 of the German CLL Study Group
    Estenfelder, Sven
    Tausch, Eugen
    Robrecht, Sandra
    Bahlo, Jasmin
    Goede, Valentin
    Ritgen, Matthias
    van Dongen, Jacques J. M.
    Langerak, Anton W.
    Fingerle-Rowson, Gunter
    Kneba, Michael
    Fischer, Kirsten
    Hallek, Michael
    Dohner, Hartmut
    Stilgenbauer, Stephan
    BLOOD, 2016, 128 (22)
  • [7] DISAPPEARANCE OF B-SYMPTOMS IN COMORBID PATIENTS RECEIVING FIRST-LINE OBINUTUZUMAB (GA101) -CHLORAMBUCIL (G-CLB) OR RITUXIMAB-CHLORAMBUCIL (R-CLB) FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
    Andres, Wenk S.
    Becker, U.
    Klawitter, S.
    Wiesner, C.
    Bernhardt, A.
    VALUE IN HEALTH, 2014, 17 (07) : A522 - A522
  • [8] Chemoimmunotherapy with Chlorambucil and the Type II CD20-Antibody GA101 In Patients with Chronic Lymphocytic Leukemia and Comorbidity: Results of the Run-In Phase of the CLL11 (BO21004) Trial.
    Goede, Valentin
    Fischer, Kirsten
    Raymonde, Busch
    Ulrich, Jaeger
    Dilhuydy, Marie-Sarah
    Wickham, Nicholas
    De Guibert, Sophie
    Fink, Anna Maria
    Hagist, Susanne
    Pflug, Natali
    Bahlo, Jasmin
    Kranz, Gabriele
    Bieska, Gabriel
    Humphrey, Kathryn
    Bishop, Helen
    Wenger, Michael
    Hallek, Michael
    BLOOD, 2010, 116 (21) : 597 - 597
  • [9] ELEVATE-TN: a phase 3, multicentre, open-label study of acalabrutinib (Ab) combined with obinutuzumab (O) or Ab alone versus O plus chlorambucil (Clb) in patients (pts) with treatment-naive chronic lymphocytic leukaemia (TN-CLL)
    Munir, T.
    Sharman, J.
    Banerji, V.
    Fogliatto, L. M.
    Herishanu, Y.
    Walewska, R.
    Follows, G.
    Karlsson, K.
    Ghia, P.
    Corbett, G.
    Walker, P.
    Egyed, M.
    Jurczak, W.
    Salles, G.
    Janssens, A.
    Cymbalista, F.
    Wierda, W.
    Coutre, S.
    Pagel, J. M.
    Skarbnik, A. P.
    Kamdar, M.
    Woyach, J. A.
    Izumi, R.
    Munugalavadla, V.
    Patel, P.
    Wang, M. H.
    Wong, S.
    Byrd, J. C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 : 26 - 28
  • [10] Obinutuzumab (GA101) 1,000 mg versus 2,000 mg in patients with chronic lymphocytic leukemia (CLL): Results of the phase II GAGE (GAO4768g) trial.
    Flynn, Joseph M.
    Byrd, John C.
    Kipps, Thomas J.
    Boxer, Michael
    Kolibaba, Kathryn S.
    Tyson, Nicola
    Hirata, Jamie H.
    Sharman, Jeff Porter
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
1